Merck (MRK) Amortizatization of Intangibles (2020 - 2026)

Merck (MRK) reported Amortizatization of Intangibles of $931.0 million for Q1 2026, up 55.95% year-over-year from $597.0 million in Q1 2025, and down 4.32% quarter-over-quarter from $973.0 million in Q4 2025.

Merck (MRK) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends

Merck (MRK) has 7 years of Amortizatization of Intangibles data on file, last reported at $931.0 million in Q1 2026.

  • Amortizatization of Intangibles for Q1 2026 came in at $931.0 million, up 55.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 billion (up 24.18% YoY), and the FY2025 annual result was $2.8 billion, up 16.62% from the prior year.
  • Amortizatization of Intangibles declined to $931.0 million in Q1 2026 per MRK's latest filing, from $973.0 million in the prior quarter.
  • Over five years, Amortizatization of Intangibles peaked at $973.0 million in Q4 2025 and troughed at $460.0 million in Q3 2022.
  • A 5-year average of $602.8 million and a median of $597.0 million in 2025 frame the typical range for Amortizatization of Intangibles.
  • The sharpest annual moves came in 2023 and 2026: Amortizatization of Intangibles declined 22.32% in 2023, then soared 55.95% in 2026.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $462.0 million in 2022, then changed by 0.0% to $462.0 million in 2023, then jumped by 46.1% to $675.0 million in 2024, then surged by 44.15% to $973.0 million in 2025, then decreased by 4.32% to $931.0 million in 2026.
  • Business Quant data shows MRK's Amortizatization of Intangibles at $931.0 million in Q1 2026, $973.0 million in Q4 2025, and $623.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn -
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn -
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn -
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn 1.70 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn 931.00 Mn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn -
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 596.00 Mn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn -
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn -
10 Novartis Ag 108.28 Bn 107.60 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2026 931.00 Mn
Mar 31, 2026 931.00 Mn
Dec 31, 2025 973.00 Mn
Dec 31, 2025 973.00 Mn
Sep 30, 2025 623.00 Mn
Sep 30, 2025 623.00 Mn
Jun 30, 2025 601.00 Mn
Jun 30, 2025 601.00 Mn
Mar 31, 2025 597.00 Mn
Mar 31, 2025 597.00 Mn
Dec 31, 2024 675.00 Mn
Dec 31, 2024 675.00 Mn
Sep 30, 2024 633.00 Mn
Sep 30, 2024 633.00 Mn
Jun 30, 2024 614.00 Mn
Jun 30, 2024 614.00 Mn
Mar 31, 2024 473.00 Mn
Mar 31, 2024 473.00 Mn
Dec 31, 2023 462.00 Mn
Dec 31, 2023 462.00 Mn